RxDoctor Payments Data

Elise Hartranft

Nurse Practitioner · Lancaster, PANPI 1962444968

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 90 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$302
  • Novo Nordisk$250
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • Scpharmaceuticals Inc.$87
  • Novartis$86
  • plus $48 from 2 others

What the payments were for

  • Food & beverage$3,01098%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$43,196
Medicare patients
350
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban892$1,010,603
VyndamaxTafamidis14$292,061
XareltoRivaroxaban221$237,405
EntrestoSacubitril/Valsartan177$232,527
JardianceEmpagliflozin118$152,653
Repatha SureclickEvolocumab104$91,472
FarxigaDapagliflozin Propanediol70$68,423
WegovySemaglutide43$54,658
MultaqDronedarone Hcl21$36,961
Praluent PenAlirocumab31$33,694
BrilintaTicagrelor37$23,219
Metoprolol Succinate1,005$15,399
VascepaIcosapent Ethyl26$12,517
Dofetilide36$12,350
OzempicSemaglutide11$9,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$14$1,302,663906 claims
Johnson & JohnsonXarelto$2,213$237,405221 claims
NovartisEntresto$86$232,527177 claims
AstraZenecaFarxiga, Brilinta$302$91,642107 claims
Novo NordiskWegovy, Ozempic$250$64,16554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →